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reach threshold before age 40. The threshold is 1 to 2
years lower if 50% rather than 20% of new angina is
considered to be incapacitating. CONCLUSION: The
methodology provides a precise, accurate method for es-
timation of CVD risk for commercial and private pilots.
The new method introduces objectivity and a level ‘play-
ing field’ for assessment of pilot cardiovascular risk.
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Inhaled steroid agents are recommended for patients with
chronic asthma. OBJECTIVE: The objective of this study
was to compare asthma-related prescription and medical
costs between a cohort of patients with inhaled steroid
use (experimental) and without inhaled steroid use (con-
trol). METHODS: 99 Medicaid patients with an asthma
diagnosis who received add-in inhaled steroids were
matched to 99 patients with an asthma diagnosis who
used therapies other than inhaled steroids. Data were col-
lected for the 6 months before the addition of an inhaled
steroid (pre-utilization phase); for the 6 months immedi-
ately after the addition (stabilization phase); and for the
6 months after the stabilization phase (post-utilization
phase). RESULTS: Compared to the pre-utilization phase,
prescription costs in the post-utilization phase increased
by an average of $57 per month for the experimental
group, while only increasing by an average of $4 per
month for the control group. Conversely, compared to
the pre-utilization phase, medical costs in the post-utili-
zation phase decreased by an average of $53 per month
for the experimental group and increased by an average
of $14 per month for the control group. These cost data
were not normally distributed. Statistical comparisons
using various methods addressing skewed data were con-
sidered (Mann-Whitney U, log transformation, and boot-
strapping). The advantages and disadvantages of using
each method will be outlined. CONCLUSION: The data
indicate that the addition of inhaled steroids increases
prescription costs while decreasing medical costs. The
level of statistical significance differs depending on the
type of test used.
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BACKGROUND: During a retrospective study of intra-
abdominal infections we found that case notes for adult
patients were destroyed or incompletely microfiched if
the patient had no contact with the hospital for six years.
OBJECTIVES: To test the hypothesis that patients with
unobtainable case notes would have higher in-hospital
mortality and that this would bias the study sample.
METHODS: Patients who might have community ac-
quired intra-abdominal infections were identified at three
acute hospitals from Scottish Morbidity Records (SMR)
for 1993 to 1995 by the following ICD9 codes: 567
(peritonitis); 540 (appendicitis); 531–534 (gastric, duode-
nal, peptic or gastrojejunal ulcers with perforation).
Medical records were obtained to validate the diagnosis
and to obtain details of antibiotic therapy and its out-
come. If medical records were unobtainable the date of
death and duration of admission were identified from the
electronic SMR record. RESULTS: A total of 867 cases
were identified. For 339 (39%) of these, case notes were
unobtainable or incomplete. SMR could be used to calcu-
late in hospital mortality and duration of stay for 334
(98%) of patients with unobtainable or incomplete medi-
cal records and 510 (97%) of patients with complete
notes. The proportion of female patients was similar
(51% versus 50%). However, the patients with unob-
tainable or incomplete records were significantly older
(median age 72 versus 53.5; P  0.0001 Wilcoxon test)
and significantly more of them died in hospital (45% ver-
sus 7%; relative risk of death in hospital 6.75; 95% CI
5.08–8.96). Median length of stay (10 days versus 9
days; P  0.27 Wilcoxon test) and total hospital cost
(£2885 versus £2746; P  0.68) were similar in the two
groups. CONCLUSION: Missing data have biased the
study sample by excluding older patients with worse out-
come. Selective destruction of case notes is an important
source of bias in retrospective outcomes studies.
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OBJECTIVE: To review the baseline similarities and dif-
ferences between olanzapine- and risperidone-treated pa-
tients, as described in epidemiologic studies, and recom-
mend a set of potential confounders that should be
addressed in such studies. METHOD: All 24 non-ran-
domized olanzapine-risperidone comparisons cited in
Medline or presented as posters at major psychiatric con-
ferences (APA, ECNP, WPA) through 1999 were in-
cluded. The direction, magnitude, and statistical signifi-
cance of all baseline comparisons of the two treatment
groups were recorded, if available. RESULTS: Across all
use, diagnosis distribution and mean age differed without
consistent direction. Comorbidities, number of different
